Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456780 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
A Phase 4 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT01456780 is a Phase 4 study that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 60 participants.
The verdict
NCT01456780, a Phase 4 study, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of meibomian gland dysfunction and validated ocular symptom assessment questionnaire.
Interventions
- DRUG Loteprednol/tobramycin
- DRUG Loteprednol
- DRUG B+L Advanced Eye Relief Lubricant Drop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-08 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01456780
The ClinicalTrials.gov registry entry for NCT01456780 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Loteprednol/tobramycin is the first listed.
NCT01456780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01456780 about?
NCT01456780 is a clinical study titled "Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis". This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy will be measured by in-vivo c...
What is the current status of trial NCT01456780?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2011-08. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01456780?
The interventions under investigation include: Loteprednol/tobramycin (DRUG), Loteprednol (DRUG), B+L Advanced Eye Relief Lubricant Drop (DRUG).
Who is sponsoring clinical trial NCT01456780?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.